Abstract:
Disclosed herein are a technetium-labeled tin nano- colloid and a method of preparing the same. The colloid is prepared by mixing a solution of radioactive technetium or a compound thereof with a solution containing tin or a compound thereof, sodium or a compound thereof, poloxamer and polyvinylpyrrolidone. The colloid, as a nano-sized particle allowing lymphatic migration, is very easily prepared, is suitably restricted to a uniform size, and has potential for use as a radiopharmaceutical in nuclear medicine, which is very useful as a radioactive tracer for identifying sentinel nodes, such as axillary lymph nodes in breast cancer.
Abstract:
Tc(technetium)-99m nano tin colloid is provided to improve in vivo stability and biocompatibility, so that it is useful for obtaining nuclear medicine image of lymphatic system and screening sentinel lymph nodes of tumor such as axillary lymph nodes. The Tc-99m nano tin colloid is prepared by mixing radioactive technetium such as 99mTc or its compound solution with a solution containing tin or its compound, sodium or its compound, poloxamer and polyvinylpyrrolidone, wherein the tin has the general formula of SnX2 in which X is halogen atom, acetate, sulfate, oxalate or succinate; the nano colloid has the particle size of 10-30 nm; and the technetium nano tin colloid further comprises phosphate buffer and a pH regulating agent including sodium bicarbonate.
Abstract:
본발명은방사성또는비방사성키토산-킬레이터하이드로겔및 이의제조방법, 및이를유효성분으로함유하는암 치료용및 색전치료용조성물에관한것이다. 본발명에따른 100 내지 300 ㎛크기로제조된키토산-킬레이터하이드로겔은종양조직으로향하는혈액의흐름을막아종양세포로의산소와영양분공급을차단함으로써암 조직에대한색전치료를위해사용될수 있으며, 특히방사성핵종이표지된키토산-킬레이터하이드로겔은방사성핵종을직접표지하거나하이드로겔형성시약물을담지함으로써, 방사성핵종의표지효율및 표지안정성이우수하여유리방사성핵종을최소화할수 있고, 방사성핵종에의한치료효과뿐만아니라약물에의한치료효과를동시에기대할수 있어병소의치료효과를높일수 있다.
Abstract:
The present invention relates to radioisotope-labeled and angiogenesis-promoting protein or peptide-loaded polymeric hydrogel, method for preparing the same, and pharmaceutical composition for preventing or treating ischemic disease comprising same as an active ingredient. The polymeric hydrogel according to the present invention directly labels radionuclides on biodegradable polymers and deposits angiogenesis-promoting protein or peptide when forming hydrogel, thereby angiogenesis-promoting protein or peptide is gradually released while staying in disease region in which polymeric hydrogel is accumulated. Therefore, waste of large amount of angiogenesis-promoting protein or peptide can be prevented; particle amount staying in ischemic diseases region can be quantified by checking bio-distribution using a gamma camera; and therapeutic effects can be predicted. In addition, the present invention releases radiation from disease region, thereby being suitably used for treating diseases such as ischemic disease. Therefore, the polymeric hydrogel according to the present invention can expect therapeutic effects by radionuclides and angiogenesis-promoting protein or peptide at the same time, and enhance therapeutic effects of disease region by quantitatively evaluating accumulation of medicines.
Abstract:
The present invention relates to a manufacturing method for quantum dots comprising: a step of manufacturing a quantum dot nanoparticle solution; a step of adding surface modification materials in the quantum dot nanoparticle solution; a step of adding water the quantum dot nanoparticle solution added with the surface modification materials and separating a water layer from a reaction solution added with the water; a step of manufacturing quantum dot nanoparticles coated with cysteamine including a process of obtaining the quantum dot nanoparticles coated with cysteamine by drying the obtained water layer after obtaining the water layer separated from the reaction solution; and a step of inducing one water-soluble monosaccharide selected from the group consisting of gluconic acid, citric acid, propionic acid, butyric acid and oleic acid.